Skip to main content
Fig. 2 | Cancer & Metabolism

Fig. 2

From: Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies

Fig. 2

Inhibition of lipogenesis suppresses cell growth in lymphoid malignancies. A Cells derived from conditional transgenic murine models with differing oncogenic drivers. Cell populations in oncogene-dependent lymphoid malignancies are sensitive to lipogenesis inhibition with TOFA, with MYC cells displaying the greatest cell population decline. B Human cell lines with differing oncogenic drivers are sensitive to lipogenesis inhibition. Values were normalized to background controls and reported as percent cell population relative to vehicle control. *P 0.1; **P 0.01; **P 0.001; ***P 0.001; ****P 0.0001. C Oleate rescue experiments. Palmitate long chain saturated fatty acids are converted into oleic acid (oleate) by SCD. Cells pre-treated with oleate (90 min) and dosed with the lipogenesis inhibitor TOFA are partially or fully rescued in all cells tested, suggesting the inhibitor is effecting de novo fatty acid synthesis. Error bars are indicated by vertical lines from sample reads across 4 technical replicates

Back to article page